| Literature DB >> 30904079 |
Wataru Nishie1, Kaisa Tasanen2.
Abstract
The study by Plaquevent et al. strongly supports the recent discovery that the use of gliptins is a risk factor for bullous pemphigoid (BP). However, regarding the phenotype of gliptin-associated BP and the necessity of gliptin withdrawal, clinical data remain scarce. We predict that future studies of gliptin-associated BP will offer valuable information concerning autoimmunity against BP180 and may also shed light on the pathology of autoimmune diseases in general.Entities:
Year: 2019 PMID： 30904079 DOI： 10.1016/j.jid.2018.11.025
Source DB: PubMed Journal: J Invest Dermatol ISSN： 0022-202X Impact factor: 8.551